🎁 Black Friday: up to 50% off of annual plans

Alice Nettleton

Stock Analyst at UBS

(0.67)
# 4,279
Out of 5,189 analysts
19
Total ratings
9.1%
Success rate
-12.2%
Average return

Stocks Rated by Alice Nettleton

AbCellera Biologics
Nov 12, 2026
Reiterated: Buy
Price Target: $18
Current: $9.69
Upside: +85.76%
Protagonist Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $184
Current: $121.40
Upside: +51.57%
Kardigan
Nov 9, 2026
Reiterated: Buy
Price Target: $25
Current: $11.54
Upside: +116.64%
Mineralys Therapeutics
Nov 6, 2026
Rated: Hold
Price Target: $29 → $19
Current: $13.66
Upside: +39.09%
Odyssey Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $27
Current: $16.96
Upside: +59.20%
Monte Rosa Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $8.64
Upside: +119.91%
BioAge Labs
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $8
Current: $4.28
Upside: +86.92%
Evommune
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $8
Current: $7.04
Upside: +13.64%
Nektar Therapeutics
Oct 11, 2026
Initiated Coverage: Hold
Price Target: $53
Current: $30.20
Upside: +75.50%
Ocular Therapeutix
Oct 11, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $5.57
Upside: +151.35%
Initiated Coverage: Buy
Price Target: $17
Current: $4.46
Upside: +281.17%
Initiated Coverage: Buy
Price Target: $120
Current: $93.47
Upside: +28.38%
Initiated Coverage: Hold
Price Target: $26
Current: $20.73
Upside: +25.42%